MSFT 435.0 0.7061% AAPL 230.65 -1.2924% NVDA 139.965 -0.9097% GOOGL 176.965 4.2934% GOOG 178.65 4.3882% AMZN 193.73 1.5197% META 594.31 0.1736% AVGO 177.28 -1.0935% TSLA 262.2401 1.0481% TSM 195.14 -0.914% LLY 831.501 -7.977% V 291.3 3.3418% JPM 224.685 0.8008% UNH 564.77 0.4696% NVO 113.15 1.0448% WMT 81.58 -0.1469% LVMUY 134.2 -1.4033% XOM 117.0342 -0.2096% LVMHF 670.0 -1.3008% MA 513.51 1.4281%

LadRx Corporation

Healthcare US LADX

1.82USD
-(-%)

Last update at 2024-10-29T20:00:00Z

Day Range

1.831.83
LowHigh

52 Week Range

0.0510.39
LowHigh

Fundamentals

  • Previous Close 1.82
  • Market Cap0.74M
  • Volume500
  • P/E Ratio4.29
  • Dividend Yield0.10%
  • EBITDA-3.87960M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM0.35

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -4.19969M -13.17666M -6.69981M -7.52202M -9.07860M
Minority interest - - - - -
Net income -4.20057M -13.17666M -6.70061M -7.16269M -12.71361M
Selling general administrative 4.54M 5.97M 6.00M 7.44M 8.08M
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation 0.02M 0.01M 0.23M 0.02M 0.03M
Ebit -4.56089M -5.98039M -6.82915M -7.86147M -8.24812M
Ebitda -4.54500M -5.96600M -6.59947M -7.50136M -7.33344M
Depreciation and amortization - - - - -
Non operating income net other - - - - -
Operating income -4.56000M -5.97998M -6.82961M -7.86167M -8.24826M
Other operating expenses - - - - -
Interest expense - - - 0.00000M 1.72M
Tax provision - 0.00000M 0.00080M 0.00080M 0.00080M
Interest income 0.01M 0.02M 0.12M 0.35M 0.36M
Net interest income 0.01M 0.02M 0.12M 0.35M -1.36017M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - 0.00080M 0.00080M 0.00080M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.25M
Total operating expenses 4.56M 5.98M 6.83M 7.86M 8.50M
Cost of revenue - - - - -
Total other income expense net 0.35M -7.21309M 0.01M -0.01252M 0.53M
Discontinued operations - - - 0.36M -3.63421M
Net income from continuing ops -4.20057M -13.17666M -6.70061M -7.52282M -9.07940M
Net income applicable to common shares -4.76195M -13.34833M -6.70061M -7.16269M -12.71361M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 2.25M 8.73M 12.06M 17.26M 22.93M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.63M 1.31M 1.09M 1.07M 0.08M
Total liab 2.22M 3.95M 3.19M 2.05M 2.56M
Total stockholder equity 0.03M 4.78M 8.87M 15.20M 20.36M
Deferred long term liab - - - - -
Other current liab 0.02M 0.00726M 0.02M 0.00412M 0.63M
Common stock 0.05M 0.04M 0.04M 0.03M 0.03M
Capital stock 1.39M 4.06M 0.04M 0.03M 0.03M
Retained earnings -488.83767M -484.07571M -470.72738M -464.02677M -456.86408M
Other liab - - - - -
Good will - - - - 0.00000M
Other assets 0.00770M 0.02M 0.02M 0.00759M 0.37M
Cash 1.37M 6.77M 10.00M 16.13M 21.37M
Cash and equivalents - - - - -
Total current liabilities 2.19M 3.73M 2.77M 2.05M 2.56M
Current deferred revenue - - - - -
Net debt - - - - -
Short term debt - - - - -
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity - - - - -
Property plant equipment 0.24M 0.43M 0.62M 0.04M 0.04M
Total current assets 2.00M 8.28M 11.42M 17.20M 22.52M
Long term investments - - - - -
Net tangible assets -1.31796M 0.75M 8.87M 15.20M 20.36M
Short term investments - - - - -
Net receivables 0.00000M 0.20M 0.33M 0.00763M 0.15M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 0.98M 1.47M 1.40M 0.89M 1.23M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.00770M 0.02M 0.02M 0.00759M 0.37M
Deferred long term asset charges - - - - -
Non current assets total 0.24M 0.45M 0.64M 0.05M 0.41M
Capital lease obligations 0.23M 0.42M 0.60M - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.00077M -0.00700M -0.02590M 0.48M -0.01148M
Change to liabilities -0.49471M 0.07M 0.19M -0.34693M -2.83124M
Total cashflows from investing activities -0.00077M -0.00700M -0.02590M 0.48M -0.01148M
Net borrowings - - - - -9.98636M
Total cash from financing activities -0.56138M 9.08M 0.04M 0.04M -5.24546M
Change to operating activities -0.34383M 0.60M -0.18663M 0.32M -6.39477M
Net income -4.20057M -13.17666M -6.70061M -7.16269M -12.71361M
Change in cash -5.39461M -3.23377M -6.12704M -5.24286M -16.12442M
Begin period cash flow 6.77M 10.00M 16.13M 21.37M 37.50M
End period cash flow 1.37M 6.77M 10.00M 16.13M 21.37M
Total cash from operating activities -4.83246M -12.30889M -6.14013M -5.71835M -10.86748M
Issuance of capital stock 0.00000M 9.18M - 0.00000M 6.51M
Depreciation 0.20M 0.20M 0.23M 0.02M 0.03M
Other cashflows from investing activities - - - 0.50M 0.50M
Dividends paid 0.56M 0.17M 0.17M 0.17M 0.17M
Change to inventory - - - - -
Change to account receivables - - - 0.14M 7.36M
Sale purchase of stock - - - - -
Other cashflows from financing activities - - - - -1.77125M
Change to netincome 0.01M 0.01M 0.33M 1.31M 2.53M
Capital expenditures 0.00077M 0.00700M 0.03M 0.02M 0.01M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.65815M 0.85M 0.00248M 0.11M -1.86978M
Stock based compensation 0.01M 0.00000M 0.33M 2.01M -
Other non cash items - - - - 1.16M
Free cash flow -4.83323M -12.31589M -6.16603M -5.74301M -10.87896M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
LADX
LadRx Corporation
- -% 1.82 4.29 - 34.48 0.51 0.61
NVO
Novo Nordisk A/S
1.17 1.04% 113.15 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S
1.95 1.76% 112.70 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
3.92 0.83% 474.27 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc
-1.92 0.21% 925.41 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

Profile

LadRx Corporation, a biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer. Further, the company's Linker Activated Drug Release technology platform consists of an organic backbone, as well as develops albumin companion diagnostic to identify patients with cancer. The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.

LadRx Corporation

11726 San Vicente Boulevard, Los Angeles, CA, United States, 90049

Key Executives

Name Title Year Born
Mr. John Y. Caloz CFO, Treasurer & Sr. VP 1952
Dr. Stephen Snowdy Ph.D. Chief Exec. Officer 1970
Molly Carey Poarch Global & U.S. Head of Corp. Communications NA
Ms. Molly Painter Pres of USA and Head of Launch & Commercial Operations 1976
Terri Stevens Chief Bus. Officer NA
Ms. Cristina Newman Corp. Sec. NA
Dr. Felix Kratz Ph.D. Sr. VP, Drug Devel. 1963

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.